However, not all studies have identified an association between Bcl-2 or Bax expression and chemoresistance and/or clinical outcome in B-CLL, implying that other factors play a role (Robertson et al, 1996; Johnston et al, 1997; Kitada et al, 1998). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.